SAN DIEGO--(BUSINESS WIRE)-- 858 Therapeutics, a biotechnology company focused on developing novel oncology therapeutics, today announced the appointment of Srini Ramanathan, Ph.D., as Chief Executive Officer. Dr. Ramanathan brings extensive drug development and clinical execution experience as the company advances its PARG inhibitor ETX-19477 in clinical trials. Dr. Jeffrey Stafford, founding CEO of 858 Therapeutics, will transition to the role of Executive Chairman of the Board of Directors.

“Over the past seven years, Jeff’s leadership has been foundational in building 858 Therapeutics from the ground up and delivering on our mission to discover impactful medicines,” said Ali Behbahani, M.D., Partner at NEA and Board Director at 858 Therapeutics. “We are delighted that he will continue to shape 858's strategic direction as Executive Chairman while we welcome Srini to steer the company into its next phase of clinical growth.”

858 Therapeutics Appoints Dr. Srini Ramanathan as Chief Executive Officer to Lead Next Phase of Company Growth

Business Wire